LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of March 11, 2019 to Sept. 10, 2019 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash

LabCorp is Scheduled to Present at the 2019 Barclays Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 5, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference . LabCorp’s presentation is planned for Tuesday, March 12, 2019 , at 8:30 a.m. (ET) . A live audio webcast of the presentation will be

LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio

LabCorp Announces 2018 Fourth Quarter and Full Year Results and Provides 2019 Guidance

Revenue: Q4 of $2.8 billion , up 2% over 2017; Full year of $11.3 billion , up 10% over 2017 Diluted EPS: Q4 of $1.56 ; Full year of $8.61 Adjusted EPS: Q4 of $2.52 , up 11% over 2017; Full year of $11.02 , up 20% over 2017 2019 Adjusted EPS guidance of $11.00 to $11.40 2019 Free Cash Flow guidance

LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to  FORTUNE  magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year.